Special Issue "Phage Therapy and Phage-Mediated Biological Control"
A special issue of Pharmaceuticals (ISSN 1424-8247).
Deadline for manuscript submissions: closed (30 November 2019).
Interests: bacteriophage therapy; bacteriophage biology; infectious diseases; biofilms
Bacteriophages or phages – the viruses of bacteria – are the most abundant and potentially most diverse organisms on Earth. The majority of these viruses are lytic, meaning that, upon producing new phages, they not only kill but also lyse their bacterial hosts. Most phages target these hosts with high precision, resulting in easily predicted pharmacodynamics. Phages, in other words, have been evolving for roughly three billion years to be extremely effective at killing bacteria but, properly chosen, have little potential to do much else, such as displaying toxicity towards bodies or environments.
Given these properties, phages have at least a potential to serve as antibacterial agents both within and outside of medicine. They have in fact been used as antibacterials clinically for nearly 100 years, longer even than chemical antibiotics have been known to science. Indeed, they represent highly diverse, easily discovered, readily characterized, inexpensively produced, low-toxicity antibacterial agents. Were we to include bacteriophages among ‘antibiotics’ then there arguably would be no antibiotic crisis.
In this Special Issue we seek submissions broadly pertaining to the subject of phage therapy, the clinical or veterinary use of bacterial viruses as antibacterial “drugs”, or, more generally, the use of phages as antibacterial biological control agents.
1. Phage therapy pharmacology
2. Ecology of Anti-Biofilm Agents I: Antibiotics versus Bacteriophages
3. Ecology of Anti-Biofilm Agents II: Bacteriophage Exploitation and Biocontrol of Biofilm Bacteria
Prof. Stephen T. Abedon
Dr. Diana R. Alves
Manuscripts should be pre-submitted directly Stephen Abedon ([email protected]) for initial editing. Research articles should strive to conform to the guidelines outlined in [editorial: “Phage Therapy Pharmacology: What Information Phage Therapy Studies Should Report”]. Following this initial editing, manuscripts should be submitted for peer review as follows:
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. Papers will be published continuously (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are refereed through a peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed Open Access quarterly journal published by MDPI.
experimental phage therapy
phage-mediated biocontrol of bacteria
plant disease biocontrol